<i>KMT2D</i> mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis

Qing-Xiao Liu(Ruijin Hospital), Weili Zhao(Shanghai Institute of Hematology)

International Journal of Biological Sciences

January 1, 2024

10.7150/ijbs.93349

Cited by 16

Related Papers

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

|The Lancet Oncology|2023|55